Skip to main content

Table 1 Baseline characteristics of hospitalized patients with COVID-19 stratified by fecal calprotectin level

From: Role of fecal calprotectin as a hypoxic intestinal damage biomarker in COVID-19 patients

Characteristics

Total

(n = 44)

FC-negative (< 50)

(n = 26)

FC-positive (≥ 50)

(n = 18)

P-value

Gender

   

0.241

 Male

23 (52.3%)

16 (61.5%)

7 (38.9%)

 

 Female

21 (47.7%)

10 (38.5%)

11 (61.1%)

 

Age (years)

48.7 ± 14.2

47.8 ± 13.9

49.9 ± 14.8

0.573

 18–59

32 (72.7%)

19 (73.1%)

13 (72.2%)

 

  ≥ 60

12 (27.3%)

7 (26.9%)

5 (27.8%)

 

Any comorbidity*

26 (59.1%)

16 (61.5%)

10 (55.6%)

0.932

Hypertension

18 (40.9%)

12 (46.2%)

6 (33.3%)

0.590

Diabetes Mellitus

22 (50%)

13 (50%)

9 (50%)

1.000

Respiratory symptoms*

 Fever

31 (70.5%)

18 (69.2%)

13 (72.2%)

1.000

 Cough

33 (75%)

19 (73.1%)

14 (77.8%)

1.000

 Dyspnea

30 (68.2%)

18 (69.2%)

12 (66.7%)

1.000

 Anosmia

4 (9.1%)

3 (11.5%)

1 (5.6%)

0.634

Gastrointestinal symptoms*

 Nausea

17 (38.6%)

1 (3.8%)

16 (88.9%)

 < 0.001

 Vomiting

13 (29.5%)

0 (0%)

13 (72.2%)

 < 0.001

 Diarrhea

14 (31.8%)

1 (3.8%)

13 (72.2%)

 < 0.001

 Abdominal pain

5 (11.4%)

1 (3.8%)

4 (22.2%)

0.142

 Decreased appetite

28 (63.6%)

13 (50%)

15 (83.3%)

0.052

Laboratory findings

 Leukocyte (/µL)

10 113.4 ± 4471.21

9465.8 ± 2802.4

11 048.9 ± 6119.6

0.775

 Thrombocyte (/µL)

335 227.3 ± 135 671.3

345 884.6 ± 135 865.9

319 833.3 ± 137 793.6

0.537

 NLR

7.5 ± 8.2

6.3 ± 3.3

9.33 ± 12.12

0.567

 Ferritin (ng/ml)

761.3 ± 664.3

774.5 ± 669.6

739.8 ± 676.8

0.736

 D-Dimer (ng/ml)

4469.4 ± 8327.3

4536.7 ± 8048.8

4372.2 ± 8950.5

0.384

 CRP (mg/L)

1.9 ± 2.4

1.6 ± 1.7

2.6 ± 3.2

0.952

  1. *Each patient might have more than one comorbidity or symptom. NLR neutrophil-to-leukocyte ratio, CRP C-reactive protein. Data are presented as numbers (percentages) or mean ± standard deviation (SD). Bold font indicates statistical significance at the P-value < 0.05